The city of Greensboro has joined a national litigation campaign suing the nation's three largest pharmacy benefit managers and three largest insulin manufacturers with the goal of lowering insulin pr ...

City attorneys allege major Pharmacy Benefit Managers (PBMs) and insulin manufacturers are conspiring to artificially inflate ...

Next up, Tremfya made a triumphant return to the 2024 roundup after falling off the rankings in 2023. The med's return came ...

So, what's next? Novo is hoping its upcoming trial for the higher-dose Wegovy in Type 2 diabetics can shake things up. But at this point, Eli Lilly is stacking wins, and Novo is running out of ...

Unions that provide health benefits to nearly a half-million workers — including many in Ohio — have filed nearly identical ...

Choosing specific antihyperglycemic agents is predicated on their effectiveness in lowering glucose, extraglycemic effects that may reduce long-term complications, safety profiles, tolerability ...

Novo Nordisk said on Friday a late-stage trial with a high-dose version of its weight loss drug semaglutide helped overweight ...

Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated ...

So, what's next? Novo is hoping its upcoming trial for the higher-dose Wegovy in Type 2 diabetics can shake things up. But at this point, Eli Lilly is stacking wins, and Novo is running out of room to ...

That means companies such as Lilly, Novo Nordisk, Sanofi and AstraZeneca will soon be competing not just on their medicines, but also on the digital services they provide to clinicians and patients.